JBS N.V., the world's largest animal protein processor, enters this earnings report at a crossroads. The company's diversified global platform — spanning beef, pork, poultry, and prepared foods across North America, South America, Europe, and Australia — has historically provided a buffer when individual segments falter. That diversification is being tested. Q1 2026 saw record net sales of approximately $21.6 billion, yet adjusted EBITDA fell roughly $400 million year-over-year, dragged down almost entirely by the U.S. beef business. With cattle supplies still tight, feed costs elevated, and U.S. plant closures announced in June, the Q2 print will reveal whether poultry strength and international gains can once again compensate. For investors, this report also marks JBS's first quarterly filing on Form 10-Q, a milestone in the company's transition to U.S. domestic reporting standards.
Analysts expect JBS to report Q2 EPS of approximately $0.32, according to the Zacks Consensus Estimate, with individual forecasts ranging from $0.17 to $0.45. The consensus revenue estimate stands near $22.96 billion, implying roughly 9.3% top-line growth from the $21.0 billion posted in Q2 2025. At the midpoint, EPS would represent a year-over-year decline of approximately 39%, continuing the pattern observed in Q1 when net profit fell 56% compared to the prior year.
The estimate revision trend has tilted bearish. Over the past three months, the Q2 consensus EPS estimate has dropped from $0.45 to the current $0.31–$0.33 range. The Zacks Earnings ESP (Expected Surprise Prediction) for JBS sits at -9.38%, suggesting that the most accurate analysts are leaning below consensus. This follows a mixed track record: JBS beat estimates in Q3 and Q2 of 2025, but missed in Q4 2025 and delivered a large miss in Q1 2026, when EPS of $0.20 came in well below the $0.28 consensus.
Key metrics to watch include U.S. Beef segment margins (negative 3.2% in Q1), Seara and JBS Brazil profitability (the primary offsetting forces last quarter), and free cash flow, which was negative $1.5 billion in Q1 due to elevated capital expenditures and working capital timing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
JBS shares closed at $14.23 on August 7, up nearly 4% on the day but still trading roughly 24% below the average analyst price target of $18.85. The stock has been volatile around recent earnings: shares fell 3.8% the day after Q1 results missed expectations, dropped 4.4% after Q2 2025 despite a beat, and gained 5.7% following the Q4 2025 report. Year-to-date, JBS has risen approximately 6.6%, underperforming the broader market. Sentiment heading into this report remains cautiously optimistic among sell-side analysts — 14 of 15 rate the stock a Buy — but the downward drift in estimates and the persistent U.S. beef overhang have tempered enthusiasm. Options markets and the stock's recent climb toward $14 suggest some positioning for a relief rally, though a miss could quickly retest the stock's 52-week lows near $11.50.
Beyond the headline numbers, investors will parse management's commentary for signals on several unfolding storylines that could shape JBS's trajectory through the remainder of 2026.
U.S. Cattle Cycle and Beef Margins. The U.S. beef segment — roughly one-third of JBS's net sales — has been the company's most significant drag. Management previously guided that 2026 would be "more challenging" than 2025, with margins potentially 1.0 to 1.5 percentage points lower. The recently announced reopening of the Mexico-U.S. cattle border is viewed by some analysts as a potential catalyst, but the timing and magnitude of any benefit remain uncertain. Watch for any updated commentary on herd rebuilding, feed costs, and the pace of plant-network optimization following the June closure announcements in Pennsylvania and Tennessee.
International Diversification and Strategic Deals. JBS's announced partnership with Indonesia's Danantara Investment Management sovereign wealth fund — which values the Australia and New Zealand assets at up to $8.5 billion — represents a creative capital-raising approach that could fund Asian expansion without straining the balance sheet. Updates on regulatory approvals and the deal timeline will be of keen interest.
Capital Allocation and Shareholder Returns. After paying a large $1.0 billion dividend in June and maintaining leverage at roughly 2.77x (within the company's 2.0–3.0x target range), the balance sheet appears stable. However, with negative free cash flow in Q1 and elevated growth capex, the pace of future dividends and the recently authorized $400 million buyback program will depend heavily on cash generation in the second half of the year.
Trade Policy and Avian Influenza. The 50% U.S. tariff on Brazilian products — including beef — and ongoing restrictions on Brazilian poultry exports to China and the European Union following the bird flu outbreak add external risk. JBS's ability to redirect product flows and manage trade friction will be a recurring theme throughout 2026.
In my analysis of earnings season opportunities across the protein sector, I frequently rely on Tickeron's AI Screener to scan for patterns and compare names like JBS against peers. This helps surface relevant trade ideas and industry context more efficiently than manual checks alone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JBS advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 22, 2026. You may want to consider a long position or call options on JBS as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
JBS moved above its 50-day moving average on July 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for JBS crossed bullishly above the 50-day moving average on July 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 241 cases where JBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JBS broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.356) is normal, around the industry mean (4.973). P/E Ratio (8.278) is within average values for comparable stocks, (36.255). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.968). Dividend Yield (0.075) settles around the average of (0.055) among similar stocks. P/S Ratio (0.163) is also within normal values, averaging (7.815).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows